Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €229.25 EUR
Change Today -1.90 / -0.82%
Volume 4.2K
As of 11:35 AM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).

sartorius stedim biotech (DIM) Snapshot

Open
€230.10
Previous Close
€231.15
Day High
€233.20
Day Low
€228.55
52 Week High
04/21/15 - €238.00
52 Week Low
10/16/14 - €120.00
Market Cap
3.5B
Average Volume 10 Days
10.6K
EPS TTM
€4.92
Shares Outstanding
15.4M
EX-Date
04/10/15
P/E TM
46.6x
Dividend
€1.30
Dividend Yield
0.57%
Current Stock Chart for SARTORIUS STEDIM BIOTECH (DIM)

Related News

No related news articles were found.

sartorius stedim biotech (DIM) Related Businessweek News

No Related Businessweek News Found

sartorius stedim biotech (DIM) Details

Sartorius Stedim Biotech S.A. provides equipment and services for the development, quality assurance, and production processes of the biopharmaceutical industry worldwide. The company’s integrated solutions cover fermentation, filtration, purification, fluid management, and lab technologies that support the biopharmaceutical industry to develop and produce drugs. It provides various products, such as media for cell cultivation; bioreactors in various sizes for cell propagation; filters for purifying cell materials; systems for storage and transportation of finished products; and single-use bags for fermentation applications. The company also offers validation and consulting services, as well as equipment installation, maintenance, and repair services. It serves manufacturers of pharmaceuticals, foods, and chemicals, as well as research and development laboratories. Sartorius Stedim Biotech S.A. was founded in 1870 and is headquartered in Aubagne, France. Sartorius Stedim Biotech S.A. is a subsidiary of Sartorius AG.

3,700 Employees
Last Reported Date: 04/20/15
Founded in 1870

sartorius stedim biotech (DIM) Top Compensated Officers

Chairman of The Board and Chief Executive Off...
Total Annual Compensation: €922.0K
Executive Vice President of Operations & IT a...
Total Annual Compensation: €552.0K
Executive Vice President of Research & Develo...
Total Annual Compensation: €549.0K
Executive Vice President of Marketing Sales &...
Total Annual Compensation: €568.0K
Compensation as of Fiscal Year 2013.

sartorius stedim biotech (DIM) Key Developments

Sartorius Stedim Biotech S.A. Reports Earnings Results for the First Quarter of 2015

Sartorius Stedim Biotech S.A. reported earnings results for the first quarter of 2015. For the quarter, the company reported sales revenue of EUR 204.4 million against EUR 154.0 million a year ago. Earnings before interest & taxes were EUR 41.3 million against EUR 24.5 million a year ago. Profit before tax was EUR 27.5 million against EUR 22.0 million a year ago. Net profit for the period attributable to shareholders of the company was EUR 18.7 million or EUR 1.22 per basic and diluted share against EUR 15.6 million or EUR 1.01 per basic and diluted share a year ago. Net cash flow from operating activities was EUR 15.9 million against EUR 13.9 million a year ago. Capital expenditure were EUR 0.2 million against EUR 0.1 million a year ago. Net debt at the end of the first quarter was EUR 89.1 million. The company reported an over proportionate increase in earnings, mainly driven by economies of scale and favorable currency effects.

Sartorius Stedim Biotech Announces Preliminary Sales Results for the First Quarter 2015; Revises Earnings Forecast for the Full Year of 2015

Sartorius Stedim Biotech announced preliminary sales results for the first quarter 2015. Based on preliminary figures sales revenue grew around 22% in constant currencies to approximately €204 million (reported gain: around 33%). Based on the results of the first three months, the company revised its forecast upwards for the full year of 2015. Sales revenue in constant currencies is now expected to increase approximately 7% to 10% (previous guidance: approx. 4% to 7%). Management projects that the company‘s underlying EBITDA margin in constant currencies will reach around 24.5% to 25% (previous guidance: around 24.0% to 24.5%). Due to the low prior-year revenue base, the company had expected above-average growth rates for this first quarter. Nevertheless, the gains supported by strong performance in all product segments were higher than projected at the beginning of the year.

Sartorius Stedim Biotech S.A., Q1 2015 Earnings Call, Apr 20, 2015

Sartorius Stedim Biotech S.A., Q1 2015 Earnings Call, Apr 20, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DIM:FP €229.25 EUR -1.90

DIM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Corning Inc $22.52 USD -0.27
General Electric Co $26.80 USD -0.05
Pall Corp $97.16 USD -0.54
Thermo Fisher Scientific Inc $130.02 USD +0.47
View Industry Companies
 

Industry Analysis

DIM

Industry Average

Valuation DIM Industry Range
Price/Earnings 47.1x
Price/Sales 4.9x
Price/Book 6.3x
Price/Cash Flow 47.2x
TEV/Sales 4.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SARTORIUS STEDIM BIOTECH, please visit www.sartorius-france.fr/fr. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.